GlassScriptPhysician profile
Madhav Boyapati
NPI 1083601181
$325.90
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $76.23 · 2021: $12.01.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $139.09 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $38.62 | 2019 | |
| Astellas Pharma US INC | $35.57 | 2019 | |
| Pfizer INC. | $27.52 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.55 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.18 | 2019 | |
| Daiichi Sankyo INC. | $17.20 | 2020 | |
| Abbvie INC. | $17.16 | 2020 | |
| Minerva Surgical, INC | $12.01 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhav Boyapati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.